Immune Dysregulation Program News and Updates

1 - 10 of 20

Multidisciplinary Task Force Develops Clinical Recommendations for Rare, Life-Threatening Hyperinflammatory Syndromes

Published on Aug 24, 2023

Hemophagocytic lymphohistiocytosis (HLH) and macrophage activation syndrome (MAS) are overlapping hyperinflammatory syndromes that involve disorganization and malfunction of the immune system, leading to widespread inflammation and organ damage. The conditions can progress rapidly, making early identification and management key for preventing organ failure and death.

CHOP-led Study Identifies Two Different Regulatory T Cell Populations

Published on Apr 07, 2023

A CHOP-led study has shown that a regulatory class of T cells descends from two different origins, one that relates to autoimmunity and one that relates to protective immunity.

Immune Dysregulation Program: for Patients Who ‘Don’t Read the Textbook’

Published on Jul 07, 2022

We all learned some simple patterns for diseases of the immune system when we were in training: immunodeficiency is “too little immune system,” autoimmunity is “too much immune system,” atopy is a “allergic immune system,” and lymphoproliferation is “a rapidly expanding immune system.”

MIS-C Patients Have Deeply Dysregulated Protein Profiles, According to New CHOP Research

Published on Jan 24, 2022

CHOP researchers found that levels of proteins in the plasma of patients with MIS-C are significantly dysregulated and share features with two other inflammatory syndromes.

CHOP Study Finds Safest Treatment for Immunodeficiency Disorder is Not Cost Effective for U.S. Patients

Published on Nov 15, 2021

Using a model developed at CHOP, researchers find high cost of treatment most likely to prevent premature death in patients with agammaglobulinemia undermines its benefits.

When Innovation Meets Necessity: CHOP Researchers’ Critical Contributions to the Battle Against COVID-19

Published on Aug 16, 2021

Since March 2020, CHOP researchers have played a vital role in combatting the COVID-19 pandemic. Read highlights of their game-changing work.

CHOP Researchers Discover New Disease that Prevents Formation of Antibodies

Published on May 05, 2021

CHOP researchers discovered a new condition, which they named PU.MA, and treated a patient with a bone marrow donation from the patient’s older brother.

Deep Immune Profiling Shows Significant Immune Activation in Children with MIS-C

Published on Mar 02, 2021

Using deep immune profiling, CHOP researchers have found children with MIS-C are extremely immune activated, more like adults with severe COVID-19.

CHOP Researchers Find Elevated Biomarker Related to Blood Vessel Damage in All Children with SARS-CoV-2 Regardless of Disease Severity

Published on Dec 08, 2020

CHOP researchers found the elevated biomarker in all children who tested positive for SARS-CoV-2, whether they were symptomatic for COVID-19 or not.

Small Study Shows Convalescent Plasma is Safe to Use in Pediatric Patients with COVID-19

Published on Sep 08, 2020

CHOP researchers show convalescent plasma appears to be a safe and possibly effective treatment for children with life-threatening cases of COVID-19.

Search

Immune Dysregulation Program News and Updates

1 - 10 of 20

Multidisciplinary Task Force Develops Clinical Recommendations for Rare, Life-Threatening Hyperinflammatory Syndromes

CHOP-led Study Identifies Two Different Regulatory T Cell Populations

Immune Dysregulation Program: for Patients Who ‘Don’t Read the Textbook’

MIS-C Patients Have Deeply Dysregulated Protein Profiles, According to New CHOP Research

CHOP Study Finds Safest Treatment for Immunodeficiency Disorder is Not Cost Effective for U.S. Patients

When Innovation Meets Necessity: CHOP Researchers’ Critical Contributions to the Battle Against COVID-19

CHOP Researchers Discover New Disease that Prevents Formation of Antibodies

Deep Immune Profiling Shows Significant Immune Activation in Children with MIS-C

CHOP Researchers Find Elevated Biomarker Related to Blood Vessel Damage in All Children with SARS-CoV-2 Regardless of Disease Severity

Small Study Shows Convalescent Plasma is Safe to Use in Pediatric Patients with COVID-19

1 - 10 of 20

Pages